Drug intelligence / Profile preview

AB4000

Development stage: Preclinical
Lead developer: Alveolus Biomedical
Modality: Small Molecules
Administration: Inhalation

Overview

AB4000 is a preclinical-stage small molecule therapeutic being developed by Alveolus Biomedical for the treatment of Acute Respiratory Distress Syndrome (ARDS). The drug is part of the company's pipeline of inhaled therapeutics, which aim to deliver treatments directly to the lungs to address critical respiratory conditions. While the specific molecular target of AB4000 has not been publicly disclosed, it is intended to mitigate the severe pulmonary inflammation and alveolar damage characteristic of ARDS. The program is currently undergoing preclinical evaluation to support future clinical development.

Beyond the preview

Go deeper on AB4000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB4000.

Explore the full profile